Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: small molecule inhibitor
Aliases prexasertib
Target CHK1/2
Partnerships In-licensed from Eli Lilly and Company; OncoSignature companion test performed by Akoya (CLIA lab) under agreement
Indications
Endometrial cancer (EC)(Phase 2)
Squamous cell carcinoma of head and neck (SCCHN)(Phase 2)
Catalysts
— second half of 2026
Status note Phase 2b registrational-intent study; lead program. SCCHN indication evaluated in an investigator-initiated trial (IIT). Received FDA Fast Track designation for ACR-368 monotherapy based on OncoSignature-predicted sensitivity. Earlier Lilly-sponsored Phase 2 included platinum-resistant ovarian cohorts, but the current program focuses on EC.
ACR-2316
Phase 2 · Active
Target WEE1/PKMYT1
Indications
Small cell lung cancer (SCLC)(Phase 2)
Squamous non-small cell lung cancer (sqNSCLC)(Phase 2)
Adenocarcinoma non-small cell lung cancer (adNSCLC)(Phase 2)
Status note Filing describes a Phase 1/2 study (dose escalation complete, two weekly dosing regimens established) now in the dose-expansion stage in AP3-identified, molecularly defined tumors. Second clinical-stage asset.
CDK11 program
Preclinical · Active
Target CDK11
Status note Internally discovered development candidates toward planned IND filing; discovered via AP3 co-crystallography platform. IND-enabling studies being initiated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
H. Lee Moffitt Cancer Center and Research Institute
—
Head and Neck Squamous Cell Carcinoma
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.